Immune Checkpoint Inhibitors for Head and Neck Squamous Cell Carcinoma-Reply

被引：0
|
作者：
Mastrolonardo, Eric V. [1 ]
Llerena, Pablo [1 ]
Curry, Joseph M. [1 ]
机构：
[1] Thomas Jefferson Univ Hosp, Dept Otolaryngol Head & Neck Surg, 925 Chestnut St,6th Floor, Philadelphia, PA 1107 USA
来源：
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY | 2025年 / 151卷 / 02期
关键词：
D O I：
10.1001/jamaoto.2024.3965
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Immune checkpoint inhibitors in sinonasal squamous cell carcinoma
    Park, Jong Chul
    Faquin, William C.
    Durbeck, Julia
    Faden, Daniel L.
    ORAL ONCOLOGY, 2020, 109
  • [32] Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice
    Wang, Hui-Ching
    Yeh, Tsung-Jang
    Chan, Leong-Perng
    Hsu, Chin-Mu
    Cho, Shih-Feng
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (20) : 1 - 22
  • [33] Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors
    Hobday, Sara B.
    Brody, Robert M.
    Kriegsman, Barry
    Basu, Devraj
    Newman, Jason
    Cohen, Roger B.
    Lukens, J. Nicholas
    Singh, Aditi
    D'Avella, Christopher A.
    Sun, Lova
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2022, 148 (10) : 918 - 926
  • [34] Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma
    Sridharan, Vishwajith
    Rahman, Rifaquat M.
    Huang, Raymond Y.
    Chau, Nicole G.
    Lorch, Jochen H.
    Uppaluri, Ravindra
    Haddad, Robert, I
    Hannah, Glenn J.
    Schoenfeld, Jonathan D.
    ORAL ONCOLOGY, 2018, 85 : 29 - 34
  • [35] Impact of therapeutic EGFR inhibition on immune checkpoint blockade in head and neck squamous cell carcinoma
    Rogers, Laura M.
    Espinosa-Cotton, Madelyn M.
    Simons, Andrean L.
    Weiner, George J.
    CANCER RESEARCH, 2016, 76
  • [36] Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma
    Ngamphaiboon, Nuttapong
    Chairoungdua, Arthit
    Dajsakdipon, Thanate
    Jiarpinitnun, Chuleeporn
    ORAL ONCOLOGY, 2023, 145
  • [37] Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Saleh, Khalil
    Daste, Amaury
    Martin, Nicolas
    Pons-Tostivint, Elvire
    Auperin, Anne
    Herrera-Gomez, Ruth Gabriela
    Baste-Rotllan, Neus
    Bidault, Francois
    Guigay, Joel
    Le Tourneau, Christophe
    Saada-Bouzid, Esma
    Even, Caroline
    EUROPEAN JOURNAL OF CANCER, 2019, 121 : 123 - 129
  • [38] Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Suzuki, Shinsuke
    Toyoma, Satoshi
    Kawasaki, Yohei
    Koizumi, Koh
    Iikawa, Nobuko
    Shiina, Kazuhiro
    Endo, Tentaro
    Abe, Tomoe
    Kouga, Teppei
    Yamada, Takechiyo
    MEDICINA-LITHUANIA, 2021, 57 (11):
  • [39] Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
    Economopoulou, Panagiota
    Anastasiou, Maria
    Papaxoinis, George
    Spathas, Nikolaos
    Spathis, Aris
    Oikonomopoulos, Nikolaos
    Kotsantis, Ioannis
    Tsavaris, Onoufrios
    Gkotzamanidou, Maria
    Gavrielatou, Niki
    Vagia, Elena
    Kyrodimos, Efthymios
    Gagari, Eleni
    Giotakis, Evangelos
    Delides, Alexander
    Psyrri, Amanda
    CANCERS, 2021, 13 (02) : 1 - 15
  • [40] Changes in serum lactate dehydrogenase as a prognostic factor in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors
    Lee, Woo Hee
    Takenaka, Yukinori
    Hosokawa, Kiyohito
    Eguchi, Hirotaka
    Suzuki, Masami
    Fukusumi, Takahito
    Suzuki, Motoyuki
    Inohara, Hidenori
    ACTA OTO-LARYNGOLOGICA, 2024, 144 (5-6) : 398 - 403
12345